Jennifer Hodge, PhD

Title: Team Lead, Rare Neurology USMA

Organization: Pfizer

Bio: Dr. Jennifer Hodge is a classically trained Immunologist who uses her expertise to understand how to therapeutically target diseases and develop medicines. She is currently the Rare Neurology Team Lead for US Medical Affairs at Pfizer. In this role, she’s responsible for leading the US Medical Affairs Duchenne Muscular Dystrophy Gene Therapy team and providing awareness, education, and engagement across the program in the US. She received her BS in Biology/Biotechnology from Worcester Polytechnic Institute and her PhD in Immunology from the University of Pennsylvania School of Medicine. She completed two post-doctoral fellowships at Harvard/Mass General and Yale before joining the faculty of Yale. She credits early experiences visiting her father’s HS biology classroom with fostering her passion for science & medicine.

Gene Therapy and Gene Editing Symposium

A brief overview of the strategy guiding efforts in gene therapy and gene editing, as well as critical updates from the companies in this space. Moderated discussion included.

Jeffrey Chamberlain, PhD


Reed Clark, PhD

Chief Science Officer, Ultragenyx Gene Therapy


Olivier Danos, PhD

Chief Scientific Officer


Jennifer Hodge, PhD

Team Lead, Rare Neurology USMA


Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics